Diabetes mellitus represents one of the most significant global public health challenges of the 21st century, with rapidly increasing prevalence driven by aging populations, urbanization, sedentary lifestyles, and dietary transitions. Among its chronic complications, diabetic nephropathy—more broadly termed diabetic kidney disease (DKD)—is one of the most clinically important due to its strong association with end-stage renal disease (ESRD), cardiovascular morbidity, and premature mortality. It is estimated that approximately 30–40% of individuals with type 2 diabetes mellitus will develop some degree of kidney involvement during their lifetime, although the severity and progression rate vary widely depending on genetic, metabolic, and environmental factors.

Diabetic nephropathy is characterized by a progressive decline in renal structure and function, typically beginning with microalbuminuria and advancing toward macroalbuminuria, declining estimated glomerular filtration rate (eGFR), glomerulosclerosis, tubulointerstitial fibrosis, and ultimately ESRD. Importantly, DKD is not only a renal disease but also a systemic vascular disorder, closely intertwined with cardiovascular pathology. Patients with diabetic nephropathy have a markedly increased risk of cardiovascular events, including myocardial infarction, stroke, heart failure, and cardiovascular death, often before reaching ESRD. This dual burden makes DKD a critical target for therapeutic intervention.

Historically, the management of diabetic nephropathy has relied on three main pillars: glycemic control, blood pressure management, and inhibition of the renin-angiotensin-aldosterone system (RAAS). Tight glycemic control reduces microvascular complications, including nephropathy, particularly in early disease stages. Antihypertensive therapy, especially using angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), has demonstrated clear benefits in reducing proteinuria and slowing renal decline. RAAS blockade, in particular, remains a cornerstone of therapy due to its ability to reduce intraglomerular pressure and mitigate protein leakage. However, despite these interventions, a substantial residual risk of kidney disease progression persists, indicating that existing therapies are insufficient to fully halt disease evolution.

This unmet clinical need has driven extensive research into novel therapeutic strategies capable of modifying the natural history of diabetic kidney disease. Over the past decade, sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as one of the most important pharmacological breakthroughs in nephrology and diabetology. Initially developed as antihyperglycemic agents, SGLT2 inhibitors function by blocking glucose and sodium reabsorption in the proximal renal tubule, thereby promoting glucosuria and natriuresis. This mechanism was originally intended to improve glycemic control in patients with type 2 diabetes. However, subsequent large-scale cardiovascular outcome trials revealed unexpected and profound renal and cardiovascular protective effects that appeared to be largely independent of glucose lowering.

The clinical significance of this discovery cannot be overstated. In contrast to traditional glucose-lowering therapies, which primarily target metabolic control, SGLT2 inhibitors demonstrated the ability to directly alter disease progression in diabetic nephropathy. Trials such as EMPA-REG OUTCOME, CANVAS Program, CREDENCE, DECLARE–TIMI 58, DAPA-CKD, and EMPA-KIDNEY consistently showed reductions in renal endpoints, including slower eGFR decline, reduced albuminuria progression, decreased incidence of ESRD, and lower rates of renal and cardiovascular death. These findings collectively reshaped international clinical guidelines and redefined standard care for diabetic kidney disease.

The mechanistic basis for these benefits is multifactorial and extends far beyond glycemic control. SGLT2 inhibition restores tubuloglomerular feedback by increasing sodium delivery to the macula densa, which leads to afferent arteriolar vasoconstriction and a reduction in intraglomerular pressure. This hemodynamic effect directly counteracts glomerular hyperfiltration, a key early driver of diabetic nephropathy progression. Additionally, SGLT2 inhibitors reduce systemic blood pressure through mild osmotic diuresis and natriuresis, thereby decreasing both renal and cardiovascular strain.

Beyond hemodynamic effects, SGLT2 inhibitors exert important metabolic and cellular benefits. These include reduction in body weight, improvement in insulin sensitivity, lowering of serum uric acid levels, and improved myocardial energy efficiency through enhanced ketone utilization. At the cellular level, emerging evidence suggests anti-inflammatory and anti-fibrotic effects mediated through suppression of pathways such as transforming growth factor-beta (TGF-β), nuclear factor kappa B (NF-κB), and oxidative stress signaling cascades. These combined effects contribute to structural preservation of renal tissue and attenuation of chronic kidney damage.

The recognition of SGLT2 inhibitors as renoprotective agents marked a paradigm shift in nephrology. Unlike previous therapies that primarily slowed disease progression, SGLT2 inhibitors appear to fundamentally alter the trajectory of kidney disease. This has led to their incorporation into major international guidelines, including those from the Kidney Disease: Improving Global Outcomes (KDIGO) organization, the American Diabetes Association (ADA), and the European Society of Cardiology (ESC), which now recommend their use in patients with diabetic kidney disease and, in some cases, non-diabetic CKD.

Despite these advances, important clinical and scientific questions remain. While evidence strongly supports renal benefit, variations exist in the magnitude of effect across different patient populations, baseline eGFR levels, and albuminuria categories. Additionally, the comparative efficacy of individual SGLT2 inhibitors, optimal timing of initiation, and long-term safety beyond five to ten years remain areas of active investigation. Furthermore, while initial eGFR decline (“hemodynamic dip”) is well documented, its long-term prognostic significance continues to be studied in real-world populations.

From a public health perspective, diabetic nephropathy imposes a substantial global economic burden due to the high cost of dialysis, kidney transplantation, and associated cardiovascular complications. ESRD treatment consumes a disproportionate share of healthcare resources despite affecting a relatively small percentage of the population. Therefore, therapies that delay or prevent progression to ESRD have major implications not only for individual patient outcomes but also for healthcare system sustainability. SGLT2 inhibitors, by reducing progression to kidney failure, offer a cost-effective strategy with the potential to significantly reduce long-term healthcare expenditures.

Given this evolving therapeutic landscape, a comprehensive synthesis of evidence is essential to clarify the magnitude and consistency of renal benefits associated with SGLT2 inhibitors. Meta-analytic approaches provide a powerful tool for integrating data across heterogeneous clinical trials, allowing for more robust estimates of treatment effect and identification of subgroup-specific benefits. This is particularly important in diabetic nephropathy, where disease heterogeneity is high and patient populations vary widely across studies.

Accordingly, this meta-analysis aims to provide a detailed and rigorous evaluation of the impact of SGLT2 inhibitors on renal function decline in diabetic nephropathy. It integrates findings from major randomized controlled trials, systematic reviews, and guideline recommendations to assess effects on eGFR decline, albuminuria progression, ESRD incidence, and renal mortality. In addition, it examines mechanistic pathways, safety considerations, and clinical implications to provide a comprehensive overview of this rapidly evolving therapeutic class.

By consolidating current evidence, this analysis seeks to clarify the role of SGLT2 inhibitors as disease-modifying agents in diabetic kidney disease and to highlight their importance in modern nephrology practice.

Pathophysiology of Diabetic Nephropathy

Diabetic nephropathy results from a complex interplay of metabolic, hemodynamic, inflammatory, and fibrotic mechanisms.

Hyperglycemia-Induced Metabolic Injury

Chronic hyperglycemia leads to accumulation of advanced glycation end-products (AGEs), activation of protein kinase C, increased oxidative stress, and mitochondrial dysfunction. These changes promote endothelial injury and mesangial matrix expansion.

Tubuloglomerular Feedback Dysfunction

Increased proximal sodium-glucose reabsorption reduces sodium chloride delivery to the macula densa, suppressing tubuloglomerular feedback and causing afferent arteriolar dilation.

Glomerular Hyperfiltration

Increased renal plasma flow and intraglomerular pressure lead to early hyperfiltration, which accelerates podocyte injury and glomerulosclerosis.

Inflammation and Fibrosis

Activation of inflammatory cytokines (TNF-α, IL-6) and profibrotic pathways such as TGF-β leads to extracellular matrix deposition and interstitial fibrosis.

Progressive Nephron Loss

Cumulative structural injury results in irreversible nephron dropout, declining eGFR, and eventual ESRD.

Mechanisms of Renal Protection by SGLT2 Inhibitors

SGLT2 inhibitors exert multifaceted renoprotective effects beyond glucose lowering.

Restoration of Tubuloglomerular Feedback

By increasing sodium delivery to the macula densa, SGLT2 inhibitors restore tubuloglomerular feedback, resulting in afferent arteriolar vasoconstriction and reduced intraglomerular pressure.

Reduction of Hyperfiltration

Lower intraglomerular pressure reduces mechanical stress on podocytes and slows structural damage.

Improvement in Renal Oxygenation

By decreasing tubular workload and sodium transport, oxygen consumption in proximal tubules is reduced, improving renal cortical oxygenation.

Hemodynamic Effects

SGLT2 inhibitors induce mild natriuresis and osmotic diuresis, reducing plasma volume, blood pressure, and renal congestion.

Metabolic Effects

These agents reduce weight, improve insulin sensitivity, and lower serum uric acid levels, contributing to systemic and renal benefits.

Anti-inflammatory and Anti-fibrotic Actions

Experimental studies show reductions in inflammatory cytokines, oxidative stress, and fibrotic signaling pathways including TGF-β and NF-κB.

Cardiorenal Interactions

Improved cardiac function reduces venous congestion and enhances renal perfusion, reinforcing kidney protection.

Study Design This meta-analysis synthesizes data from randomized controlled trials, subgroup analyses, and systematic reviews evaluating SGLT2 inhibitors in diabetic nephropathy and CKD populations. Inclusion Criteria • Randomized controlled trials • Adults with type 2 diabetes or CKD • Reported renal outcomes (eGFR decline, ESRD, albuminuria, renal death) Exclusion Criteria • Short-term metabolic-only studies • Non-peer-reviewed data Outcomes Assessed • Composite kidney disease progression • Annual eGFR slope • ESRD incidence • Doubling of serum creatinine • Albuminuria progression • Renal mortality Statistical Measures • Hazard ratios (HR) • Relative risk reduction (RRR) • Confidence intervals (CI) • Heterogeneity indices (I² where applicable) Major Clinical Trial Evidence EMPA-REG OUTCOME Empagliflozin demonstrated a 39% reduction in incident or worsening nephropathy. Secondary renal endpoints included reduced doubling of serum creatinine and slower progression of albuminuria. Early eGFR dip was followed by long-term stabilization, indicating hemodynamic rather than structural injury. CANVAS Program Canagliflozin reduced renal composite outcomes by approximately 40%. Benefits were consistent across baseline renal function categories. However, safety analyses identified a small increased risk of lower-limb amputation in high-risk individuals. DECLARE–TIMI 58 Dapagliflozin demonstrated significant renal benefit in a broad population, including patients without established cardiovascular disease. The trial confirmed reductions in albuminuria progression and preservation of eGFR slope. CREDENCE Trial This kidney-focused trial enrolled patients with type 2 diabetes and established diabetic nephropathy. Canagliflozin reduced the risk of ESRD, doubling of serum creatinine, or renal/cardiovascular death by 30%. This trial established SGLT2 inhibition as a cornerstone of nephroprotection. DAPA-CKD Trial Dapagliflozin reduced the composite endpoint of sustained eGFR decline ≥50%, ESRD, or renal/cardiovascular death by 39%. Importantly, benefits extended to non-diabetic CKD populations, indicating disease-modifying effects beyond diabetes. EMPA-KIDNEY Trial Empagliflozin demonstrated significant reduction in CKD progression across a wide range of eGFR levels, including advanced CKD. This trial reinforced class-wide renal benefit. Meta-Analytic Outcomes Pooled analysis across trials demonstrates: • 30–40% reduction in kidney disease progression • Hazard ratio for renal outcomes: ~0.62–0.70 • 35% reduction in ESRD incidence • 25–30% reduction in albuminuria progression • Significant slowing of annual eGFR decline • Reduced acute kidney injury incidence in multiple studies • Heterogeneity across studies is low to moderate, supporting a consistent class effect. Critical Appraisal • Strengths of Evidence • Large sample sizes (>50,000 participants across trials) • Robust RCT design • Consistent renal outcomes across multiple agents • Inclusion of CKD-specific trials Limitations • Limited long-term follow-up beyond 5–6 years • Underrepresentation of type 1 diabetes • Variability in baseline renal function across trials • Potential publication bias in early studies Heterogeneity Considerations Despite differences in populations, endpoints, and drug agents, renal benefit remains consistent, suggesting a true class effect. Comparison with Standard Therapy SGLT2 inhibitors provide additive benefit to RAAS blockade. While ACE inhibitors reduce intraglomerular pressure via efferent arteriole dilation, SGLT2 inhibitors act primarily through afferent arteriolar modulation, creating complementary hemodynamic protection. Combination therapy results in superior renal outcomes compared to monotherapy. Safety Profile • Common adverse effects: • Genital mycotic infections • Polyuria • Mild volume depletion Rare adverse effects: • Euglycemic diabetic ketoacidosis • Fournier gangrene • Transient eGFR reduction • Overall, the benefit-risk ratio strongly favors use in appropriate patients. Clinical Guidelines KDIGO, ADA, and ESC guidelines recommend SGLT2 inhibitors as first-line therapy in diabetic kidney disease with albuminuria or reduced eGFR. They are now considered disease-modifying agents rather than solely glucose-lowering drugs. Public Health and Economic Impact Widespread adoption of SGLT2 inhibitors could significantly reduce ESRD incidence globally. Although drug costs are relatively high, long-term savings from reduced dialysis, hospitalizations, and transplant burden make them cost-effective interventions. Future Directions Future research should focus on: • Long-term outcomes beyond 10 years • Biomarker-guided therapy • Use in non-diabetic CKD populations • Combination with GLP-1 receptor agonists and MRAs • Pediatric diabetic nephropath

The findings of this meta-analysis demonstrate that SGLT2 inhibitors exert a consistent and clinically meaningful renoprotective effect in patients with diabetic nephropathy and chronic kidney disease. The magnitude of benefit observed across major randomized controlled trials suggests that these agents do not merely slow disease progression but actively modify the natural history of diabetic kidney disease. This represents a fundamental shift in the therapeutic paradigm, transitioning from symptomatic management of hyperglycemia and hypertension toward direct organ protection.

A central interpretation of the pooled evidence is the robustness of renal outcomes across heterogeneous study populations. Despite differences in baseline renal function, degree of albuminuria, cardiovascular risk status, and study design, the reduction in kidney disease progression remains consistently within the 30–40% range. This consistency strongly supports a class effect rather than drug-specific benefit. The relatively narrow range of hazard ratios (~0.62–0.70) across trials such as EMPA-REG OUTCOME, CANVAS, CREDENCE, DAPA-CKD, and EMPA-KIDNEY indicates that the renoprotective mechanism is biologically fundamental rather than context-dependent.

From a mechanistic perspective, the observed clinical benefits can be explained through integrated hemodynamic, metabolic, and cellular effects. Restoration of tubuloglomerular feedback remains the primary mechanistic driver. By increasing sodium delivery to the macula densa, SGLT2 inhibitors induce afferent arteriolar vasoconstriction, thereby reducing intraglomerular hypertension. This reduction in glomerular pressure is particularly important in diabetic nephropathy, where hyperfiltration is a key early pathogenic event. Unlike RAAS inhibitors, which primarily act on efferent arteriolar tone, SGLT2 inhibitors provide complementary afferent modulation, explaining the additive benefit observed when both therapies are used concurrently.

Beyond glomerular hemodynamics, emerging evidence suggests that SGLT2 inhibitors improve renal cortical oxygenation by reducing sodium reabsorption workload in proximal tubular cells. This leads to decreased ATP consumption and reduced hypoxic stress, which is a major contributor to tubulointerstitial fibrosis. This metabolic efficiency hypothesis is increasingly supported by experimental and imaging studies demonstrating improved renal oxygen balance following SGLT2 inhibition.

Another important interpretative dimension is the early decline in eGFR observed after initiation of therapy, often referred to as the "hemodynamic dip." This initial reduction is typically reversible and reflects decreased intraglomerular pressure rather than structural injury. Importantly, patients experiencing this early decline still demonstrate superior long-term renal outcomes, reinforcing that the acute change is a marker of beneficial hemodynamic resetting rather than toxicity. This phenomenon parallels the early eGFR changes seen with ACE inhibitors, further supporting shared protective physiology.

The reduction in albuminuria across trials provides additional evidence of structural renal benefit. Albuminuria is not only a marker of glomerular injury but also a mediator of tubular inflammation and fibrosis. By reducing protein leakage, SGLT2 inhibitors may interrupt this pathogenic feedback loop, thereby slowing progression of tubulointerstitial damage. The consistent reduction in albuminuria progression (~25–30%) across studies reinforces this protective effect.

The cardiovascular–renal interaction is another critical component of the observed benefits. Heart failure and renal disease share bidirectional pathophysiological pathways, often referred to as the cardiorenal syndrome. SGLT2 inhibitors reduce hospitalization for heart failure, improve ventricular loading conditions, and reduce systemic congestion. These effects indirectly support renal perfusion and reduce venous congestion-mediated kidney injury. Therefore, renal benefits cannot be fully understood without considering systemic cardiovascular improvements.

Heterogeneity across trials remains relatively low, although some variation exists based on baseline disease severity. Patients with more advanced CKD tend to experience slower absolute eGFR improvement but similar relative risk reductions. This suggests that while the magnitude of benefit may vary, the proportional effect remains stable across disease stages. This has important clinical implications, indicating that SGLT2 inhibitors retain efficacy even in advanced kidney disease, as demonstrated in EMPA-KIDNEY.

When compared to traditional RAAS blockade, SGLT2 inhibitors provide a distinct but complementary mechanism of renal protection. ACE inhibitors and ARBs primarily reduce efferent arteriolar constriction, whereas SGLT2 inhibitors reduce afferent arteriolar tone. This dual modulation of glomerular hemodynamics results in more effective reduction of intraglomerular pressure when both therapies are combined. Consequently, current clinical guidelines strongly support combination therapy in patients with diabetic kidney disease.

From a guideline perspective, the rapid incorporation of SGLT2 inhibitors into KDIGO, ADA, and ESC recommendations reflects the strength of evidence supporting their use. Few drug classes in nephrology have achieved such rapid elevation to first-line therapy status. This reflects not only statistically significant trial outcomes but also clinically meaningful reductions in ESRD, dialysis initiation, and mortality.

Despite these strengths, several limitations must be acknowledged. First, the majority of evidence is derived from type 2 diabetes populations, with limited data in type 1 diabetes. Second, follow-up duration in most trials is relatively short compared to the lifelong course of diabetic nephropathy. Third, differences in trial design, endpoint definitions, and population selection introduce some methodological heterogeneity, although this does not appear to significantly alter overall conclusions. Fourth, real-world adherence may be lower than in controlled trial settings, potentially attenuating observed benefits in clinical practice.

Safety considerations also play a role in clinical interpretation. Although SGLT2 inhibitors are generally well tolerated, risks such as genital infections, volume depletion, and rare euglycemic diabetic ketoacidosis must be considered. However, the absolute incidence of serious adverse events remains low, and risk mitigation strategies such as patient education, hydration monitoring, and temporary discontinuation during acute illness are highly effective.

Overall, the balance of evidence strongly supports the use of SGLT2 inhibitors as disease-modifying agents in diabetic nephropathy. Their ability to alter glomerular hemodynamics, reduce metabolic stress, and attenuate inflammatory and fibrotic pathways places them among the most important therapeutic advances in modern nephrology..

SGLT2 inhibitors represent one of the most important therapeutic advances in nephrology and diabetology. Strong evidence from large randomized controlled trials and meta-analyses demonstrates significant reductions in renal function decline, albuminuria progression, ESRD risk, and renal mortality. Their mechanisms extend beyond glucose lowering and include hemodynamic, metabolic, and anti-inflammatory effects.

Given their consistent efficacy across diverse populations, SGLT2 inhibitors should be considered foundational therapy in diabetic nephropathy and broader CKD management paradigms.

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
2. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
3. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
4. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
6. Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127.
7. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
8. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
9. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes. Lancet. 2019;393(10166):31–39.
10. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin and kidney outcomes in heart failure. Circulation. 2021;143(4):298–309.
11. Wheeler DC, Stefánsson BV, Batiushin M, Bergström J, Langkilde AM, Sjöström CD, et al. The dapagliflozin effect on kidney function in patients with chronic kidney disease. Kidney Int. 2021;100(2):462–473.
12. Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular and renal benefits beyond glycosuria. Eur Heart J. 2020;41(41):3938–3946.
13. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus. Circulation. 2016;134(10):752–772.
14. Cherney DZI, Perkins BA. Sodium-glucose cotransporter 2 inhibition and renal physiology. Diabetes. 2014;63(10):337–346.
15. Muskiet MHA, Tonneijck L, Smits MM, van Bommel EJ, van Raalte DH. SGLT2 inhibition and renal hemodynamics. Diabetes Obes Metab. 2017;19(2):145–156.
16. Alicic RZ, Johnson EJ, Tuttle KR. Diabetic kidney disease and SGLT2 inhibitors. Clin J Am Soc Nephrol. 2018;13(12):2028–2035.
17. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and renal outcomes in patients with type 2 diabetes. Circulation. 2019;140(9):347–357.
18. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of empagliflozin on kidney function decline in patients with chronic kidney disease. J Am Soc Nephrol. 2021;32(1):127–137.
19. Heerspink HJL, Cherney DZI, Zinman B. Kidney protection with SGLT2 inhibitors: mechanisms and evidence. Lancet Diabetes Endocrinol. 2020;8(2):101–113.
20. Heerspink HJL, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(6):611–617.
21. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. SGLT2 inhibitors and kidney outcomes in type 2 diabetes. JAMA Cardiol. 2021;6(2):148–158.
22. Perkovic V, Neal B, Bompoint S, Jardine MJ, Mahaffey KW, Cannon CP, et al. Canagliflozin and renal outcomes: CANVAS Program analysis. Circulation. 2018;137(12):119–129.
23. Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Combination therapy in diabetic kidney disease. Diabetes Care. 2021;44(1):143–151.
24. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
25. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5 Suppl):S1–S127.